Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2026-03-03 @ 8:15 AM
Study NCT ID:
NCT03722420
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-10-28
First Post:
2018-10-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Sponsor:
Il-Yang Pharm. Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-12-28
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2018-10-25
First Submit QC Date:
None
Study First Post Date:
2018-10-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-24
Last Update Post Date:
2024-10-28
Last Update Post Date Type:
ACTUAL